Literature DB >> 10588320

In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole.

E Dannaoui1, F Persat, M F Monier, E Borel, M A Piens, S Picot.   

Abstract

The MICs of amphotericin B and itraconazole for 230 isolates of Aspergillus spp., comprising 156 Aspergillus fumigatus, 20 Aspergillus terreus, 22 Aspergillus flavus, 17 Aspergillus nidulans and 15 Aspergillus niger, were determined by a broth microdilution method with RPMI 1640 medium. No isolate was detected with an MIC of amphotericin B >2 mg/L. Itraconazole MICs >16 mg/L were detected for four Aspergillus fumigatus and one Aspergillus nidulans isolates.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10588320     DOI： 10.1093/jac/44.4.553

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  20 in total

1.  Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.

Authors:  Paul E Verweij; Debbie T A Te Dorsthorst; Anthonius J M M Rijs; Hilly G De Vries-Hospers; Jacques F G M Meis
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

Review 2.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 3.  Clinical implications of globally emerging azole resistance in Aspergillus fumigatus.

Authors:  Jacques F Meis; Anuradha Chowdhary; Johanna L Rhodes; Matthew C Fisher; Paul E Verweij
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-12-05       Impact factor: 6.237

4.  Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.

Authors:  L A Beernaert; F Pasmans; L Van Waeyenberghe; G M Dorrestein; F Verstappen; F Vercammen; F Haesebrouck; A Martel
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

5.  Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.

Authors:  Jesús Guinea; Sandra Recio; Teresa Peláez; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

Review 6.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

7.  A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.

Authors:  E Mellado; G Garcia-Effron; L Alcázar-Fuoli; W J G Melchers; P E Verweij; M Cuenca-Estrella; J L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

8.  Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit.

Authors:  Eric Dannaoui; Frédéric Gabriel; Manuel Gaboyard; Gaëlle Lagardere; Lucile Audebert; Gilles Quesne; Sandrine Godichaud; Paul E Verweij; Isabelle Accoceberry; Marie-Elisabeth Bougnoux
Journal:  J Clin Microbiol       Date:  2017-08-16       Impact factor: 5.948

9.  Azole cross-resistance in Aspergillus fumigatus.

Authors:  J Mosquera; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

10.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.